NFKB1 and colitis: Glucose-lysine Maillard reaction products (Glc-Lys MRPs) ameliorate DSS-induced colitis, increase glutathione content as well as antioxidant activities, and suppress the inflammatory cytokines and NF-κB [70, 71]; thus they can be used for preventing or treating IBD.